Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 115, Issue 12, Pages 1504-1512
Publisher
Springer Nature
Online
2016-11-23
DOI
10.1038/bjc.2016.372
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
- (2016) Fabrice Barlesi et al. LANCET
- First-line erlotinib versus gemcitabine/cisplatin in patients with advancedEGFRmutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study
- (2015) Y.-L. Wu et al. ANNALS OF ONCOLOGY
- Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma
- (2015) Zoltan Lohinai et al. Journal of Thoracic Oncology
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations
- (2015) Chao-Hua Chiu et al. Journal of Thoracic Oncology
- Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
- (2015) James C-H Yang et al. LANCET ONCOLOGY
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
- (2015) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer
- (2015) Oscar Arrieta et al. LUNG CANCER
- Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis
- (2015) Sabrina Rossi et al. Molecular Diagnosis & Therapy
- Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing
- (2014) H. A. Yu et al. ANNALS OF ONCOLOGY
- High proportion of rare and compound epidermal growth factor receptor mutations in an Australian population of non-squamous non-small-cell lung cancer
- (2014) E. Stone et al. INTERNAL MEDICINE JOURNAL
- Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors
- (2014) Hyun Sun Woo et al. INVESTIGATIONAL NEW DRUGS
- Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q
- (2014) Satoshi Watanabe et al. Journal of Thoracic Oncology
- A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)
- (2014) Yuankai Shi et al. Journal of Thoracic Oncology
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- Comparison of the Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer according to the Type of Epidermal Growth Factor Receptor Mutation
- (2014) Satoshi Igawa et al. ONCOLOGY
- Patients with Exon 19 Deletion Were Associated with Longer Progression-Free Survival Compared to Those with L858R Mutation after First-Line EGFR-TKIs for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
- (2014) Yaxiong Zhang et al. PLoS One
- Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology
- (2014) Daoud Sie et al. CELLULAR ONCOLOGY
- Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)
- (2013) S. Dearden et al. ANNALS OF ONCOLOGY
- Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network
- (2013) M. Beau-Faller et al. ANNALS OF ONCOLOGY
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
- (2013) H. A. Yu et al. CLINICAL CANCER RESEARCH
- Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer
- (2013) Bhumsuk Keam et al. International Journal of Clinical Oncology
- Activating Germline R776H Mutation in the Epidermal Growth Factor Receptor Associated With Lung Cancer With Squamous Differentiation
- (2013) Jan van Noesel et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions
- (2013) Geoffrey R. Oxnard et al. Journal of Thoracic Oncology
- EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics
- (2013) M. E. Arcila et al. MOLECULAR CANCER THERAPEUTICS
- Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
- (2013) H. Yasuda et al. Science Translational Medicine
- First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung
- (2012) Ji-Youn Han et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinicopathological Characteristics of 11 NSCLC Patients with EGFR-Exon 20 Mutations
- (2012) Marius Lund-Iversen et al. Journal of Thoracic Oncology
- Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non–Small-Cell Lung Carcinoma and is Antibody Dependent
- (2012) Chris M.J. Conklin et al. Journal of Thoracic Oncology
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Effectiveness of Tyrosine Kinase Inhibitors on "Uncommon" Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non-Small Cell Lung Cancer
- (2011) J.-Y. Wu et al. CLINICAL CANCER RESEARCH
- Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations
- (2011) R. Rosell et al. CLINICAL CANCER RESEARCH
- Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
- (2011) Masahiro Fukuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations
- (2011) Tommaso De Pas et al. Journal of Thoracic Oncology
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung Cancer: An Analytical Database
- (2010) Samuel Murray et al. Journal of Thoracic Oncology
- Complex Mutations in the Epidermal Growth Factor Receptor Gene in Non-small Cell Lung Cancer
- (2010) Akito Hata et al. Journal of Thoracic Oncology
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials
- (2009) D. M. Jackman et al. CLINICAL CANCER RESEARCH
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response
- (2008) J.-Y. Wu et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now